The Amylin case is a 2-day trial to determine the validity of a "poison put" takeover defense that would protect Amylin's board of directors from being replaced. Carl Icahn, who owns 9.4% of Amylin, and the hedge fund Eastbourne Capital, which ow... View Proceeding
Settlement hearing. The court previously held a hearing on a on motion for a preliminary injunction in suit seeking to block acquisition of Genentech Inc (NYSE) by Roche Holdings Inc. View Proceeding
Suit alleging that various pharmaceutical companies failed to disclose the potential side effects of Fen Phen, a popular diet medication, which included primary hypertension and valve disease. View Proceeding
Suit brought by the state's attorney general against Pfizer's Pharmacia unit and other pharmaceutical manufacturers alleging they overcharged the state's Medicaid system. Litigation over "average wholesale prices" for medication charged to state M... View Proceeding
The plaintiffs trade secret misappropriation claims arise out of Coronary Artery Bypass Graft (CABG) clinical drug trials for Bextra, a second generation COX-2 inhibitor.According to plaintiff non-profit Ischemia Research & Education Foundati... View Proceeding
